Immune-Modified Glasgow Prognostic Score Predicts Therapeutic Effect of Pembrolizumab in Recurrent and Metastatic Head and Neck Cancer.

IF 4.4 2区医学 Q1 ONCOLOGY Cancers Pub Date : 2024-12-03 DOI:10.3390/cancers16234056

Natsuko Ueda, Masashi Kuroki, Hirofumi Shibata, Manato Matsubara, Saki Akita, Tatsuhiko Yamada, Rina Kato, Ryota Iinuma, Ryo Kawaura, Hiroshi Okuda, Kosuke Terazawa, Kenichi Mori, Ken Saijo, Toshimitsu Ohashi, Takenori Ogawa

{"title":"Immune-Modified Glasgow Prognostic Score Predicts Therapeutic Effect of Pembrolizumab in Recurrent and Metastatic Head and Neck Cancer.","authors":"Natsuko Ueda, Masashi Kuroki, Hirofumi Shibata, Manato Matsubara, Saki Akita, Tatsuhiko Yamada, Rina Kato, Ryota Iinuma, Ryo Kawaura, Hiroshi Okuda, Kosuke Terazawa, Kenichi Mori, Ken Saijo, Toshimitsu Ohashi, Takenori Ogawa","doi":"10.3390/cancers16234056","DOIUrl":null,"url":null,"abstract":"Background: Previously, we proposed that the immune-modified Glasgow Prognostic Score (imGPS), which adds the lymphocyte count to the mGPS, is helpful as a prognostic marker for patients with head and neck squamous cell carcinoma. In this study, we investigated the imGPS as a marker for the therapeutic effect of pembrolizumab in treating recurrent and metastatic head and neck cancer (RMHNC).Methods: This study included RMHNC patients who were treated with pembrolizumab from December 2019 to April 2024. ALB, CRP, lymphocyte counts, neutrophil-to-lymphocyte ratios (NLRs), mGPSs, and imGPSs were extracted as biomarkers, and the response rate and prognosis were analyzed for each.Results: A total of 54 patients were enrolled. Lymphocyte counts were correlated with the overall response rates (ORRs) (p = 0.0082). Although the mGPS did not show significant differences in ORRs, imGPSs revealed a significant difference (p = 0.013). CRP, ALB, and lymphocyte counts were correlated with overall survival (OS) and/or progression-free survival (PFS). NLRs, mGPSs, and imGPSs were also correlated with OS and/or PFS, with imGPSs showing the greatest area under the curve (OS; AUC = 0.795, PFS; AUC = 0.754).Conclusions: This study demonstrates that the imGPS is an excellent predictive marker for the therapeutic effect and prognosis of pembrolizumab for RMHNC. The imGPS can be employed with daily blood tests, highlighting the potential to forecast the impact of the ICI with high reliability.","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"16 23","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11640115/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers16234056","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Previously, we proposed that the immune-modified Glasgow Prognostic Score (imGPS), which adds the lymphocyte count to the mGPS, is helpful as a prognostic marker for patients with head and neck squamous cell carcinoma. In this study, we investigated the imGPS as a marker for the therapeutic effect of pembrolizumab in treating recurrent and metastatic head and neck cancer (RMHNC).

Methods: This study included RMHNC patients who were treated with pembrolizumab from December 2019 to April 2024. ALB, CRP, lymphocyte counts, neutrophil-to-lymphocyte ratios (NLRs), mGPSs, and imGPSs were extracted as biomarkers, and the response rate and prognosis were analyzed for each.

Results: A total of 54 patients were enrolled. Lymphocyte counts were correlated with the overall response rates (ORRs) (p = 0.0082). Although the mGPS did not show significant differences in ORRs, imGPSs revealed a significant difference (p = 0.013). CRP, ALB, and lymphocyte counts were correlated with overall survival (OS) and/or progression-free survival (PFS). NLRs, mGPSs, and imGPSs were also correlated with OS and/or PFS, with imGPSs showing the greatest area under the curve (OS; AUC = 0.795, PFS; AUC = 0.754).

Conclusions: This study demonstrates that the imGPS is an excellent predictive marker for the therapeutic effect and prognosis of pembrolizumab for RMHNC. The imGPS can be employed with daily blood tests, highlighting the potential to forecast the impact of the ICI with high reliability.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

免疫修饰格拉斯哥预后评分预测 Pembrolizumab 对复发和转移性头颈癌的治疗效果

背景：之前，我们提出免疫修饰的格拉斯哥预后评分（imGPS），将淋巴细胞计数添加到mGPS中，有助于作为头颈部鳞状细胞癌患者的预后标志物。在这项研究中，我们研究了imGPS作为派姆单抗治疗复发和转移性头颈癌（RMHNC）疗效的标志物。方法：本研究纳入了2019年12月至2024年4月期间接受派姆单抗治疗的RMHNC患者。提取ALB、CRP、淋巴细胞计数、中性粒细胞与淋巴细胞比值（NLRs）、mGPSs和imGPSs作为生物标志物，并分析其有效率和预后。结果：共入组54例患者。淋巴细胞计数与总有效率（ORRs）相关（p = 0.0082）。虽然mGPS在orr中无显著差异，但imgps在orr中有显著差异（p = 0.013）。CRP、ALB和淋巴细胞计数与总生存期（OS）和/或无进展生存期（PFS）相关。NLRs、mGPSs和imGPSs也与OS和/或PFS相关，其中imGPSs曲线下面积最大(OS；Auc = 0.795, pfs；Auc = 0.754)。结论：本研究表明imGPS是派姆单抗治疗RMHNC疗效和预后的良好预测指标。imGPS可用于日常血液检查，突出了高可靠性预测ICI影响的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancers Medicine-Oncology

CiteScore

8.00

自引率

9.60%

发文量

5371

审稿时长

18.07 days

期刊介绍： Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.